MAGNESIUM-CAPITAL
16.4.2024 09:33:33 CEST | Business Wire | Press release
Magnesium Capital, the Energy Transition buyout specialist, is delighted to announce the successful close of its inaugural Fund, Magnesium Capital I, at its hard cap of €135m, exceeding the €100m Fund target. The final close occurred less than a year after the Fund’s first close with Magnesium attracting blue-clip institutional investors from the US, Europe and the UK.
Magnesium focuses on profitable European companies with proven technologies or tech-enabled services that are positively impacting the decarbonisation of the production, distribution and consumption of energy. The team has been backing the buyouts of such businesses for a number of years on a direct deal basis. Since inception, Magnesium has completed seven platform investments, signed six follow-on acquisitions and exited two investments for 4.2x gross MOIC. The combined impact of these portfolio companies already directly contributes to the avoidance of over 30 million tonnes of CO2 equivalent per annum.
Ian Jones, Managing Partner, commented: “Magnesium’s distinctive investment strategy, reputation for adding value by working closely with management teams, and the positive environmental impact of our portfolio companies, generated considerable investor interest resulting in the Fund being significantly over-subscribed.”
Matts Lundgren, Managing Partner, commented: “We are grateful for the support of our long-standing investors and also to our new limited partners for their belief in our strategy and our team. With the support of our impressive roster of investors, we now have access to deep pools of capital to continue developing and executing on our differentiated pipeline of opportunities to support the growth and development of companies poised to make a major contribution to the decarbonisation of our energy system.”
Triago served as exclusive global placement agent, Simpson Thacher & Bartlett as legal counsel and PricewaterhouseCoopers as tax advisors.
About Magnesium Capital
Magnesium Capital LLP is a private equity firm specialising in buyouts of high growth, profitable businesses that support the energy transition. It invests throughout Europe and the UK. It likes to partner with entrepreneurial management teams and support them on their next stage of growth. Magnesium looks for businesses with certain competitive advantages in their core technology or tech-led service that have a positive impact on the way we either produce, distribute, or consume energy. Magnesium takes controlling stakes in each of its investments, but considers significant minority positions in certain circumstances. Magnesium is based in London, United Kingdom.
https://www.magnesiumcapital.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240416988248/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Visa Unveils New Services to Modernize Dispute Resolution Process1.4.2026 15:00:00 CEST | Press release
Fraudulent disputes and administrative inefficiencies drive billions in avoidable economic costsSix new and enhanced dispute resolution tools utilize AI and proprietary technology to help provide issuers, acquirers and merchants with increased visibility into costly fraud expenses Visa (NYSE: V), a global leader in digital payments, today announced six new dispute resolution tools designed to reduce the billions of dollars lost annually to inefficient, outdated dispute processes. The expanded suite of dispute resolution services is being designed to help merchants and financial institutions cut administrative costs, reduce fraud-related losses and redirect those resources toward growth, innovation and customer experience. Disputes remain one of the most persistent friction points in commerce, driving rising costs for merchants and financial institutions while simultaneously leaving consumers frustrated and confused. In 2025, Visa processed 106 million disputes globally, a 35% increase
Rimini Street Announces Debt Reduction and Amendment to its Credit Agreement1.4.2026 15:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™, and the leading third-party support provider for Oracle, SAP and VMware software, today announced first quarter debt reduction activities and a recent amendment to its credit agreement. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260401160360/en/ Rimini Street Announces Debt Reduction and Amendment to its Credit Agreement Debt reduction activities during the first quarter of 2026 totaled $10.9 million, reducing the Company’s outstanding term loan to $58.4 million as of March 31, 2026. The Company’s credit agreement was amended effective as of March 27, 2026 to increase to $20.0 million the value of Company common stock that could be repurchased per annum, beginning with the Company’s 2026 fiscal year and for each fiscal year thereafter, with a revised total of $50.0 million in permitted stock repurchases from the period beginning January
Neuphonic and Rapport Bring Real-Time Digital Humans to Everyday Hardware1.4.2026 15:00:00 CEST | Press release
New partnership delivers sub-100ms, fully on-device avatars — unlocking scalable, lifelike AI characters for games, film and interactive media Neuphonic and Rapport (a division of Speech Graphics) today announced a partnership to deliver what they believe is among the first fully real-time, photorealistic digital human systems running entirely on standard CPU hardware. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260401782320/en/ Rapport and Neuphonic announce a partnership to deliver next-generation conversational AI experiences. The collaboration combines Neuphonic’s ultra-low latency text-to-speech technology with Rapport, an interactive AI avatar role play platform powered by production-proven real-time facial and full-body animation technology from Speech Graphics, used in video games such as Call of Duty, The Last of Us Part II and Hogwarts Legacy. Together, the system generates natural voice, perfectly synchronised
Netceed Strengthens Board with Global Infrastructure and Technology Leaders1.4.2026 14:00:00 CEST | Press release
Netceed, a global leader in delivering supply chain solutions across broadband, data center and energy infrastructure, today announced the appointment of Franck Bruel, Jan Frykhammar and Stacey Thompson to advise as strategic advisors to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260401045867/en/ Franck Bruel Following the recently announced recapitalization of the Netceed Group and under the chairmanship of Rajeev Suri, the company is strengthening its Board with globally recognized leaders across telecommunications infrastructure, industrial distribution, energy infrastructure and hyperscale technology. Collectively, the new appointees bring decades of leadership experience across some of the world’s most influential infrastructure and technology companies, reflecting Netceed’s ambition to play a leading role in the next generation of global digital, AI and energy infrastructure. Rajeev Suri, Ch
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press release
-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein--Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported b
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom